Skiba Katarzyna, Adamczak Marcin, Wiecek Andrzej
Katedra i Klinika Nefrologii, Endokrynologii i Chorób Przemiany Materii, Slaski Uniwersytet Medyczny w Katowicach.
Przegl Lek. 2011;68(7):391-5.
Osteoporosis is a systemic skeletal disorder characterized by impaired bone strength, leading to an increased risk of fracture. Patients with severe osteoporosis and multiple vertebral fractures are particularly at risk for subsequent osteoporotic fractures independently of antiresorptive therapy. The effective treatment of osteoporosis should prevent fractures through normalization of bone mass and improving bone microarchitecture. Recombinant human parathyroid hormone (teriparatide) is an anabolic (bone forming) agent. The aim of this study was to describe the results of treatment with teriparatide (Forsteo) of three patients with severe osteoporosis. Teriparatide has proved to be effective in preventing bone loss. New osteoporotic fracture has not occurred in two patients. Treatment with teriparatide was safe and well tolerated.
骨质疏松症是一种全身性骨骼疾病，其特征是骨强度受损，导致骨折风险增加。患有严重骨质疏松症和多发性椎体骨折的患者，无论抗吸收治疗如何，后续发生骨质疏松性骨折的风险都特别高。骨质疏松症的有效治疗应通过使骨量正常化和改善骨微结构来预防骨折。重组人甲状旁腺激素（特立帕肽）是一种促合成（成骨）药物。本研究的目的是描述三名严重骨质疏松症患者接受特立帕肽（复泰奥）治疗的结果。特立帕肽已被证明在预防骨质流失方面有效。两名患者未发生新的骨质疏松性骨折。特立帕肽治疗安全且耐受性良好。
